A population-based study of progression to metastatic prostate cancer in Australia.
نویسندگان
چکیده
BACKGROUND We used population-based data from the New South Wales Central Cancer Registry (CCR) to describe the patterns of progression to metastatic disease in Australian men diagnosed with non-metastatic prostate cancer. METHODS Data for all non-metastatic prostate cancer cases diagnosed 1993-2002 and followed to the end of 2007 were analysed. The outcome was progression to metastatic disease, identified by metastatic episode notifications in the CCR or by prostate cancer death. Factors associated with metastatic disease progression were identified using Cox regression models. RESULTS Of the 32,643 men with non-metastatic prostate cancer at diagnosis 43.1% had localised disease, 5.1% had regional spread and 51.9% had unknown stage. After a median of 6.8 years of follow-up 6708 cases (20.6%) had developed distant metastases. The risk of developing metastatic disease was significantly higher for those with regional (adjusted HR=2.65, 95% CI: 2.40-2.93) or unknown initial stage (adjusted HR=1.70, 95% CI: 1.61-1.80), for older men (65-74 years: HR=1.43, 95% CI: 1.33-1.53; >74 years: HR=2.73, 95% CI: 2.55-2.93), and those living in inner regional (HR=1.11, 95% CI: 1.04-1.18) or rural areas (HR=1.24, 95% CI: 1.14-1.36) or more disadvantaged areas (middle tertile: HR=1.09, 95% CI: 1.02-1.16; most disadvantaged: HR=1.12, 95% CI: 1.04-1.19). The risk of developing metastatic disease decreased over calendar time (adjusted HR=0.98, 95% CI: 0.97-0.99 per year). CONCLUSIONS After a median follow-up of 6.8 years more than 1 in 5 men diagnosed with non-metastatic prostate cancer developed distant metastases. This estimate of the overall risk of developing metastatic disease in the population, and the geographical disparities identified, can inform the planning of required cancer services.
منابع مشابه
Roles of Renin-Angiotensin System in the Regulation of Prostate Cancer Bone Metastasis: A Critical Review
Mestastatic prostate cancer cells (MPCCs) frequently metastasize to bone, which is a “favorite soil” for colonization and proliferation of MPCCs. Prostate cancer bone mestastasis is tightly associated with tumor-induced bone lesions, most commonly caused from the etiological imbalance between osteoblastic bone formation and osteoclastic bone resorption, and from the anti-tumor immune response. ...
متن کاملAssessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening
Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...
متن کاملMetastatic Tumors to Craniofacial Skeleton: Analysis of Two Cases and Review of the Literature
Craniofacial skeletal metastasis is a rare presentation of advanced prostate cancer. This is a report of a 69-year-old man who presented with numbness of the right lower lip and recently ill-fitting lower denture. Based on the medical history of benign prostate hyperplasia (BPH) and suspicion of a metastatic tumor, prostate core needle biopsy was performed. Histology of the prostate biopsy con...
متن کاملبررسی نقش بیومارکری ژن ها در تمیز دادن نمونه های سرطانی متاستازی و اولیه از بافت نرمال در سرطان پروستات
Background & Aims: Prostate cancer (PCa) is the second most common cancer in men worldwide. The identification of sensitive and specific biomarkers in tissue and serum is of utmost importance to reduce the mortality of prostate cancer. Since that, early detection of cancer has an important role in treatment, in this study we tried to identify genes that could potentially effective in early...
متن کاملPhase IIa Clinical Trial of Trans-1-Amino-3-18F-Fluoro- Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer
Objective(s): We performed a phase IIa clinical trial of trans-1-amino-3-18Ffluoro-cyclobutane carboxylic acid (anti-18F-FACBC), a synthetic amino acid analog for PET, in patients with metastatic prostate cancer. Methods: The study subjects consisted of 10 untreated prostate cancer patients having lymph node and/or bone metastasis. Five patients underwent whole-body PET 5 and 30 min after intra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cancer epidemiology
دوره 39 4 شماره
صفحات -
تاریخ انتشار 2015